Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

469 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock.
van Diepen S, Reynolds HR, Stebbins A, Lopes RD, Džavík V, Ruzyllo W, Geppert A, Widimsky P, Ohman EM, Parrillo JE, Dauerman HL, Baran DA, Hochman JS, Alexander JH. van Diepen S, et al. Among authors: alexander jh. Crit Care Med. 2014 Feb;42(2):281-8. doi: 10.1097/CCM.0b013e31829f6242. Crit Care Med. 2014. PMID: 23982033 Clinical Trial.
Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials.
Galla JM, Mahaffey KW, Sapp SK, Alexander JH, Roe MT, Ohman EM, Granger CB, Armstrong PW, Harrington RA, White HD, Simoons ML, Newby LK, Califf RM, Topol EJ. Galla JM, et al. Among authors: alexander jh. Am Heart J. 2006 Jan;151(1):16-24. doi: 10.1016/j.ahj.2005.01.045. Am Heart J. 2006. PMID: 16368286
Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery.
Goyal A, Alexander JH, Hafley GE, Graham SH, Mehta RH, Mack MJ, Wolf RK, Cohn LH, Kouchoukos NT, Harrington RA, Gennevois D, Gibson CM, Califf RM, Ferguson TB Jr, Peterson ED; PREVENT IV Investigators. Goyal A, et al. Among authors: alexander jh. Ann Thorac Surg. 2007 Mar;83(3):993-1001. doi: 10.1016/j.athoracsur.2006.10.046. Ann Thorac Surg. 2007. PMID: 17307447 Clinical Trial.
Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study.
Dzavík V, Cotter G, Reynolds HR, Alexander JH, Ramanathan K, Stebbins AL, Hathaway D, Farkouh ME, Ohman EM, Baran DA, Prondzinsky R, Panza JA, Cantor WJ, Vered Z, Buller CE, Kleiman NS, Webb JG, Holmes DR, Parrillo JE, Hazen SL, Gross SS, Harrington RA, Hochman JS; SHould we inhibit nitric Oxide synthase in Cardiogenic shocK 2 (SHOCK-2) investigators. Dzavík V, et al. Among authors: alexander jh. Eur Heart J. 2007 May;28(9):1109-16. doi: 10.1093/eurheartj/ehm075. Epub 2007 Apr 25. Eur Heart J. 2007. PMID: 17459901 Clinical Trial.
469 results